Finally, we compared the ability of GPR35 agonists to suppress osteoclast activity to that of current osteoporosis drugs, denosumab and alendronic acid, and showed TRAP activity was similarly suppressed under all conditions. This evidence concerns the gene GPR35 and osteoporosis.